These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30800130)

  • 1. Th17 Cells Paradoxical Roles in Melanoma and Potential Application in Immunotherapy.
    Chen C; Gao FH
    Front Immunol; 2019; 10():187. PubMed ID: 30800130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct host preconditioning regimens differentially impact the antitumor potency of adoptively transferred Th17 cells.
    Wittling MC; Knochelmann HM; Wyatt MM; Rangel Rivera GO; Cole AC; Lesinski GB; Paulos CM
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38945552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanoma.
    Melief SM; Visser M; van der Burg SH; Verdegaal EME
    Cancer Immunol Immunother; 2017 Jul; 66(7):913-926. PubMed ID: 28401257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive immunotherapy involving recombinant human M-CSF and R24 anti-melanoma antibody induces human T-cell infiltration into human melanoma xenografts.
    Conlon KC; Anver MR; Longo DL; Ortaldo JR; Murphy WJ
    J Immunother Emphasis Tumor Immunol; 1996 Sep; 19(5):317-23. PubMed ID: 8941871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of melanoma.
    Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
    Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Strategies for gene therapy of melanoma].
    Dummer R; Davis-Daneshfar A; Döhring C; Döbbeling U; Burg G
    Hautarzt; 1995 May; 46(5):305-8. PubMed ID: 7607892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapse of melanoma after successful adoptive T-cell therapy: escape through inflammation-induced phenotypic melanoma cell plasticity.
    Somasundaram R; Herlyn M
    Pigment Cell Melanoma Res; 2013 Jan; 26(1):2-4. PubMed ID: 23387000
    [No Abstract]   [Full Text] [Related]  

  • 8.
    Hu X; Majchrzak K; Liu X; Wyatt MM; Spooner CJ; Moisan J; Zou W; Carter LL; Paulos CM
    Cancer Res; 2018 Jul; 78(14):3888-3898. PubMed ID: 29769201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of malignant melanoma.
    Oratz R; Bystryn JC
    Dermatol Clin; 1991 Oct; 9(4):669-82. PubMed ID: 1718648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma-induced immunosuppression and its neutralization.
    Umansky V; Sevko A
    Semin Cancer Biol; 2012 Aug; 22(4):319-26. PubMed ID: 22349515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The adoptive transfer of cultured T cells for patients with metastatic melanoma.
    Yang JC
    Clin Dermatol; 2013; 31(2):209-19. PubMed ID: 23438384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Principles of adoptive cell therapy based on "Tumor Infiltrating Lymphocytes"].
    Martins F; Orcurto A; Michielin O; Coukos G
    Rev Med Suisse; 2016 May; 12(519):989-93. PubMed ID: 27424426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanoma immunotherapy: new dreams or solid hopes?
    Maio M; Parmiani G
    Immunol Today; 1996 Sep; 17(9):405-7. PubMed ID: 8854555
    [No Abstract]   [Full Text] [Related]  

  • 14. Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion.
    Bowers JS; Nelson MH; Majchrzak K; Bailey SR; Rohrer B; Kaiser AD; Atkinson C; Gattinoni L; Paulos CM
    JCI Insight; 2017 Mar; 2(5):e90772. PubMed ID: 28289713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for advanced melanoma: Current knowledge and future directions.
    Nakamura K; Okuyama R
    J Dermatol Sci; 2016 Aug; 83(2):87-94. PubMed ID: 27302423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A role of immunotherapy in metastatic malignant melanoma.
    Allen T; Gundrajakuppam L
    Cent Nerv Syst Agents Med Chem; 2012 Sep; 12(3):182-8. PubMed ID: 22697295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy and experimental approaches for metastatic melanoma.
    Atkins MB
    Hematol Oncol Clin North Am; 1998 Aug; 12(4):877-902, viii. PubMed ID: 9759585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.
    Tähtinen S; Blattner C; Vähä-Koskela M; Saha D; Siurala M; Parviainen S; Utikal J; Kanerva A; Umansky V; Hemminki A
    J Immunother; 2016; 39(9):343-354. PubMed ID: 27741089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Future of malignant stage I melanoma. Immunology and immunotherapy].
    Nicolas JF; Berthier O; Trillet-Lenoir V; Claudy A; Revillard JP
    Ann Dermatol Venereol; 1995; 122(5):324-35. PubMed ID: 8572476
    [No Abstract]   [Full Text] [Related]  

  • 20. [A malignus melanoma immunterápiájának lehetoségei].
    Ladányi A
    Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.